Assessing endocrine resistance: monitoring circulating ESR1 mutations in Irosustat-treated ER positive breast cancer
Analysis of serial plasma samples revealed highly dynamic ctESR1m during AI treatment and frequent detection of polyclonal ctESR1m in patients (both with SD and PD) recruited to the IRIS study. These findings, albeit in a limited sample size, underscore the challenge of targeting a single ESR1 mutation and emphasise the need for careful patient selection, specifically those with wild-type ESR1, in trials investigating sequential estrogen-lowering therapies.
Authors
- Karen Page (ORCID: https://orcid.org/0000-0003-0440-9244)
- Rebecca C. Allsopp (ORCID: https://orcid.org/0000-0003-4887-8632)
- Jinli Luo (ORCID: https://orcid.org/0000-0002-9241-5283)
- Marc Wadsley (ORCID: https://orcid.org/0000-0002-7014-2595)
- Robert Hastings (ORCID: https://orcid.org/0000-0001-8703-127X)
- Luke Martinson
- R. Charles Coombes (ORCID: https://orcid.org/0000-0002-4811-1100)
- Emmanuel Acheampong (ORCID: https://orcid.org/0000-0002-5338-3258)
- Jacqui Shaw (ORCID: https://orcid.org/0000-0003-4227-503X)
- Carlo Palmieri (ORCID: https://orcid.org/0000-0001-9496-2718)
Institutions
- University of Liverpool (GB)
- Leicester Royal Infirmary (GB)
- Hammersmith Hospital (GB)
- Birmingham Research Park (GB)
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2025-12-09
- DOI
- https://doi.org/10.1007/s10549-025-07857-6
- Primary Topic
- Estrogen and related hormone effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cancer Research UK
- National Institute for Health and Care Research
- University of Leicester
- NIHR Leicester Biomedical Research Centre